2026 ICD-10-CM Diagnosis Code T36.6X5SAdverse effect of rifampicins, sequela

ICD-10-CM Codes›S00–T88›T36-T50›T36

ICD-10-CM T36.6X5S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T36.6X5S is a billable ICD-10-CM diagnosis code for adverse effect of rifampicins, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as antituberculous drug adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T36.6X5S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of rifampicins, sequela
Short Description
Adverse effect of rifampicins, sequela
Same as the full description in the CMS dataset.
Parent Code
T36.6X5
Adverse effect of rifampicins

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT36Poisoning by, adverse effect of and underdosing of systemic antibiotics
This CodeT36.6X5SAdverse effect of rifampicins, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T36.6X5S.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T36.6X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Antituberculous drug adverse reaction
  • Drug-induced uveitis
  • Rifabutin adverse reaction
  • Rifabutin-induced anterior uveitis
  • Rifampicin adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of systemic antibiotics (T36). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Rifabutin

    a broad-spectrum antibiotic that is being used as prophylaxis against disseminated mycobacterium avium complex infection in hiv-positive patients.

  • Rifampin

    a semisynthetic antibiotic produced from streptomyces mediterranei. it has a broad antibacterial spectrum, including activity against several forms of mycobacterium. in susceptible organisms it inhibits dna-dependent rna polymerase activity by forming a stable complex with the enzyme. it thus suppresses the initiation of rna synthesis. rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (from gilman et al., goodman and gilman's the pharmacological basis of therapeutics, 9th ed, p1160)

  • Rifaximin

    a synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of gastroenteritis caused by escherichia coli infections. it may also be used in the treatment of hepatic encephalopathy.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect		Under­dosing
AnsamycinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifabutinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifamideT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifampicinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
Rifampicin::with isoniazidT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifampinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifamycinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6
RifaximinT36.6X1T36.6X2T36.6X3T36.6X4T36.6X5T36.6X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T36.6X5S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E930.6 Adv eff antmycob antbiot
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T36.6X5SOverview

Is T36.6X5S (Adverse effect of rifampicins) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of rifampicins, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T36.6X5S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of rifampicins itself has resolved, not the original event.

What MS-DRG does T36.6X5S group to?

On inpatient claims, adverse effect of rifampicins, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T36.6X5S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of rifampicins, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T36.6X5S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of rifampicins, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.